A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial.

Citation:
Marques Da Costa ME, Zaidi S, Scoazec JY, …….. Malinge S, Mercher T, Tabone-Eglinger S, et al. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors. Commun Biolog. 2023;6(1)

Keywords:
Biological Specimen Banks; Disease Models; Heterografts;
Leukemia; Neoplasms; precision Medicine; biobank; genetics; xenograft

Abstract:
Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial.